394 related articles for article (PubMed ID: 14652277)
1. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277
[TBL] [Abstract][Full Text] [Related]
2. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
4. Type and duration of exogenous hormone use affects breast cancer histology.
Kumar AS; Cureton E; Shim V; Sakata T; Moore DH; Benz CC; Esserman LJ; Hwang ES
Ann Surg Oncol; 2007 Feb; 14(2):695-703. PubMed ID: 17103262
[TBL] [Abstract][Full Text] [Related]
5. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women.
Gammon MD; Hibshoosh H; Terry MB; Bose S; Schoenberg JB; Brinton LA; Bernstein JL; Thompson WD
Cancer Epidemiol Biomarkers Prev; 1999 May; 8(5):413-9. PubMed ID: 10350436
[TBL] [Abstract][Full Text] [Related]
6. Risk of breast cancer in post-menopausal women using hormone replacement therapy.
Ratanawichitrasin A; Reansuwan W; Ratanawichitrasin S; Bhodhisuwan K; Kongpatanakul S
J Med Assoc Thai; 2002 May; 85(5):583-9. PubMed ID: 12188389
[TBL] [Abstract][Full Text] [Related]
7. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk.
Shantakumar S; Terry MB; Paykin A; Teitelbaum SL; Britton JA; Moorman PG; Kritchevsky SB; Neugut AI; Gammon MD
Am J Epidemiol; 2007 May; 165(10):1187-98. PubMed ID: 17337757
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Olsson HL; Ingvar C; Bladström A
Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
[TBL] [Abstract][Full Text] [Related]
9. Statins and breast cancer in postmenopausal women without hormone therapy.
Eaton M; Eklof J; Beal JR; Sahmoun AE
Anticancer Res; 2009 Dec; 29(12):5143-8. PubMed ID: 20044629
[TBL] [Abstract][Full Text] [Related]
10. The relation of reproductive factors to mortality from breast cancer.
Daling JR; Malone KE; Doody DR; Anderson BO; Porter PL
Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):235-41. PubMed ID: 11895871
[TBL] [Abstract][Full Text] [Related]
11. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
12. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment.
Ursic-Vrscaj M; Bebar S
Eur J Surg Oncol; 1999 Apr; 25(2):146-51. PubMed ID: 10218456
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy and mammographic screening outcomes in Western Australia.
Crouchley K; Wylie E; Khong E
J Med Screen; 2006; 13(2):93-7. PubMed ID: 16792833
[TBL] [Abstract][Full Text] [Related]
14. An analysis of the effect of selection bias on the association of hormone replacement therapy and breast cancer risk.
Csizmadi I; Friedenreich CM; Bryant HE; Courneya KS
Chronic Dis Can; 2005; 26(2-3):73-9. PubMed ID: 16251013
[TBL] [Abstract][Full Text] [Related]
15. Ethnic differences in breast cancer in Hawai'i: age, stage, hormone receptor status, and survival.
Braun KL; Fong M; Gotay CC; Chong CD
Pac Health Dialog; 2004 Sep; 11(2):146-53. PubMed ID: 16281692
[TBL] [Abstract][Full Text] [Related]
16. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer.
Slattery ML; Potter JD; Curtin K; Edwards S; Ma KN; Anderson K; Schaffer D; Samowitz WS
Cancer Res; 2001 Jan; 61(1):126-30. PubMed ID: 11196149
[TBL] [Abstract][Full Text] [Related]
17. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.
Schuetz F; Diel IJ; Pueschel M; von Holst T; Solomayer EF; Lange S; Sinn P; Bastert G; Sohn C
Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414
[TBL] [Abstract][Full Text] [Related]
18. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.
Quick SK; Shields PG; Nie J; Platek ME; McCann SE; Hutson AD; Trevisan M; Vito D; Modali R; Lehman TA; Seddon M; Edge SB; Marian C; Muti P; Freudenheim JL
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1082-7. PubMed ID: 18483329
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease.
Windler E; Zyriax BC; Eidenmüller B; Boeing H
Maturitas; 2007 Jul; 57(3):239-46. PubMed ID: 17292571
[TBL] [Abstract][Full Text] [Related]
20. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study.
Wellejus A; Olsen A; Tjonneland A; Thomsen BL; Overvad K; Loft S
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2137-42. PubMed ID: 16172222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
